I really do believe it is way too soon to put much value of the non HIV franchises. The Suitor is only concerned with the HIV Franchise, first and foremost, Adjunct. Mono is even a relatively long shot for the Suitor. Though if Adjunct is compelling, I do believe that puts a lot more credence towards Mono and a little more towards Autoimmune. Data always sways!
News 
Market Data 
Discover 
